Baiao Zhihui and Gilead Science signed an asset purchase agreement
海角七号
发表于 2024-11-21 12:33:08
165
0
0
According to AI News, Analytical BioSciences Limited (referred to as "BioSciences") and its subsidiary Shanghai Xingsai Biotechnology Co., Ltd. recently announced the signing of an asset purchase agreement with Gilead Sciences Inc. This agreement involves a new method pioneered by Baiao Zhihui in cancer immunotherapy, which induces the formation of tertiary lymphoid structures (TLS) by reprogramming cancer associated fibroblasts (CAFs) in the tumor microenvironment.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Baiao Zhihui and Gilead Science signed an asset purchase agreement
- Jing Shun: Optimistic about investment opportunities in risky assets
- Increase Chinese assets! Wall Street funds bet on Chinese asset ETF call options
- Geely takes big action to integrate Jike Lynk&Co's new company, aiming for an annual production and sales target of one million vehicles
- Dialogue with Gan Jiayue, CEO of Geely Automobile Group: 99800 yuan is not a "price war", Geely pursues technology to reduce costs
- Baidu and Geely have started the internal transfer process to pay social security for employees of Jiyue in November
- It's extremely concerning! Geely and Baidu issue joint statement
- Chinese assets suddenly exploded! Multiple Chinese concept stocks rose by over 10%
